Information Provided By:
Fly News Breaks for July 26, 2018
BSX
Jul 26, 2018 | 07:28 EDT
Canaccord analyst Jason Mills said Q2 represented another stellar quarter for Boston Scientific. He said it is still a great time to invest in the company as management raised guidance and he favors the long-term strategy to deliver organic growth via technology differentiation and global breadth in targeted med-tech markets. Mills reiterated his Buy rating and raised his price target to $39 from $36 on Boston Scientific shares.
News For BSX From the Last 2 Days
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.